Portfolio | 迈博斯生物与奕安济世合并成立Transcenta Holding， 加速推进建设国际化整合型生物制药公司

（中国，香港、上海、苏州，杭州，2019 年 1 月 2 日）- 奕安济世生物药业 (HJB) 和迈博斯生物 (MabSpace) 今日宣布合并，成立Transcenta Holding (Transcenta)。作为一家国际化的生物制药公司，Transcenta具备生物药物研究、开发、法规和生产的全流程整合能力。两家公司合并后，迈博斯生物创始人、董事长兼首席执行官钱雪明博士将担任Transcenta首席执行官，奕安济世共同创始人兼首席执行官赵奕宁博士将担任Transcenta执行董事长。

迈博斯生物成立于 2013 年，是一家专注于创新生物药发现、临床研究和商业化开发的临床阶段生物技术公司，重点关注癌症和其他疾病的抗体治疗领域。迈博斯生物总部位于香港，在苏州生物医药产业园拥有占地5000平方米的集成化抗体发现和开发中心。迈博斯生物 60 多人的团队中拥有涵盖药物发现、转化研究、工艺开发、临床研究和商业化开发和法规事务的专业人才。凭借专有的免疫耐受突破为基础的抗体开发平台技术，迈博斯生物已建立起由创新首仿或快速改进型抗体项目组成的丰富产品管线，在研的十余个药物涉及肿瘤、眼病和肾病领域。

创立于 2016 年的奕安济世致力于设计和应用创新生物工艺技术，加速生物制剂的研发和生产。奕安济世通过位于上海、杭州和波士顿三地的业务中心，构建全球研发和生产网络，并聚集了百余名来自全球各地的科学家、临床医生和生物工程师。凭借逾 13000 平方米和运用灵活性生产模块的 GMP生产基地，以及新一代连续生产工艺，奕安济世能够快速开发高质量的生物治疗药物，显著降低生产成本，为全球更多患者提供经济有效的生物药。通过许可引进，奕安济世已获得数个同类首个下一代免疫治疗抗体项目在中国或全球市场的权利。

通过结合奕安济世和迈博斯生物的互补优势，Transcenta内部实现了生物疗法发现、开发和生产领域的前后道整合，并拥有了一支在生物药发现和研发领域具备丰富的国际行业经验的资深团队。此外，Transcenta已成功搭建了全球业务布局：在苏州设有药物发现和转化研究中心，在杭州拥有工艺与产品开发中心和生产基地，并在上海、北京和美国波士顿分别设有临床开发中心。Transcenta将致力于缩短从药物靶标到BLA的时间，并应用高质量的新一代 GMP设施，支持内部管线和战略合作伙伴管线分子的开发和商业化。

“非常高兴两家公司成功完成合并。Transcenta将全面整合迈博斯生物和奕安济世在药物发现、开发和生产方面的优势，” Transcenta共同创始人兼执行董事长赵奕宁博士表示，“迈博斯生物已建立起十分丰富的产品管线，包括数 10 个临床前和临床药物，结合奕安济世在工艺与临床研发以及高度集成化药物生产方面的优势，Transcenta将通过具有价格竞争力的高质量生物药，持续为全球患者创造更多价值。”

“我们对全力支持迈博斯生物和奕安济世战略合并的投资者表示衷心感谢。奕安济世和迈博斯生物合并之后，我们能够进一步扩大业务规模，大幅加快创新药物管线的研发和商业化，使Transcenta成为一家具有真正意义上的全流程整合能力并专注生物药开发的国际化生物技术公司。这不仅能缩短研发时间，还能通过以更低的价格让高质量生物药惠及患者，同时使公司获取持续的利润回报，实现长期增长。我们希望Transcenta能成为常青的生物科技公司，向患者提供高质量的创新药物，为股东创造价值。” Transcenta共同创始人兼首席执行官钱雪明博士补充道。

截至目前，奕安济世与迈博斯生物已获得来自知名投资机构共计约 1.6 亿美元的资金，投资方包括礼来亚洲基金、淡马锡、红杉资本、ARCH Venture Partners、泰康和腾跃基金等。Transcenta将积极拓展与全球生物技术公司的战略合作，进一步丰富产品管线和提升技术实力。

关于ARCH Venture Partners：

ARCH Venture Partners 是美国最大的早期科技行业风投公司之一。ARCH 投资并参与创立了由科研型大学、国家实验室、企业研究团体和企业家们成立的 230 多家专注生命科学和自然科学领域的创新公司。

关于礼来亚洲基金：

礼来亚洲基金 (LAV) 成立于 2008 年，是领先的生物医药投资机构，在中国上海、香港和美国加州帕罗奥多市均设有办公室。礼来亚洲基金致力于成为杰出创业者寻求智慧资本时的优选合作伙伴，共创以突破性产品战胜疾病并改善人类健康的伟大公司。

关于红杉资本中国基金：

红杉资本始终致力于帮助创业者成就基业常青的伟大公司，为成员企业带来丰富的全球资源和宝贵的历史经验。46 年来，红杉资本投资了众多创新企业和产业潮流的领导者。红杉资本中国基金作为「创业者背后的创业者」，专注于科技/传媒、医疗健康、消费品/服务、工业科技四个方向的投资机遇。十四 年来，红杉资本中国基金投资了超过500 家具有鲜明技术特征、创新商业模式、具备高成长性和高发展潜力的企业。

关于泰康：

泰康是中国领先的大型保险和金融服务集团，业务涵盖保险、资管及医养三大领域。医疗领域是泰康的重要投资领域，泰康在该领域的投资组合包括药明康德、迈瑞医疗、信达生物等公司。

关于淡马锡：

淡马锡成立于 1974 年，是一家总部位于新加坡的国际投资公司。我们的机构遍布全球。截至 2018 年 3 月 31 日，淡马锡的投资组合价值为3080 亿新元（相当于2350 亿美元、1.48 万亿人民币），主要分布在新加坡和亚洲其它地区。

关于腾跃：

腾跃基金是纽约一家专门从事中国股权投资的长线基金。基于基本面分析，腾跃运用严谨的投资过程，利用其全球视野及本土专业知识，投资中国内地和海外的企业。

BFC Group担任此次交易的独家财务顾问。 

汉坤律师事务所担任此次合并交易的法律顾问。

Sidley Austin LLP 担任迈博斯生物的法律顾问。

了解更多信息：

媒体联系：

Jingyuan Qin ([e-mail])

Kathy Yuan ([e-mail])

投资者联系：

Jonathan Zhao ([e-mail])

Xueming Qian ([e-mail])

业务发展联系：

Kathy Yuan ([e-mail])

Chun Li ([e-mail])

---

英文新闻:

MabSpace Biosciences Merged with Hangzhou Just Biotherapeutics to Form Transcenta Holding, a Fully Integrated Leading Global Biotherapeutics Company

(Hong Kong, Shanghai, Suzhou & Hangzhou, China, January 2^nd, 2019) Hangzhou Just Biotherapeutics (HJB) and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd., (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of MabSpace, will serve as chief executive officer while Dr. Jonathan Yining Zhao, co-founder and CEO of HJB, will be the executive chairman of the combined company, respectively.

Founded in 2013, MabSpace is a clinical stage biotech company focused on discovery, clinical research and commercial development of innovative biologic medicines, particularly in the field of antibody-based therapeutics for cancer and other diseases. MabSpace is headquartered in Hong Kong, with a 50,000 square feet fully-integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park, China. MabSpace employs a sixty-person team covering discovery and translational research, process development, clinical and commercial development and regulatory affairs. With its proprietary antibody generation platform technology, Immune Tolerance Breaking Technology, MabSpace has established a pipeline of over ten innovative fast follow-on or first-in-class antibody programs in oncology, ophthalmology as well as nephrology.

Founded in 2016, HJB is dedicated to designing and applying innovative bioprocessing technologies to accelerate biologics R&D and manufacturing. HJB has global sites established in Shanghai, Hangzhou and Boston, and a global talent pool of over 100 scientists, clinicians and bioengineers. With its 140,000 square feet state-of-the-art POD-based manufacturing facility and next-generation continuous processing technology, HJB can enable speedy development of high-quality biotherapeutic agents and significantly reduce the cost of production to make these biologic medicines more affordable to a global population. Through in-licensing, HJB has obtained either China or global rights for several first-in-class next-generation immunotherapy antibody programs. 

By leveraging and combining the complimentary capabilities of HJB and MabSpace, Transcenta will be equipped with a senior team with extensive global industrial experience in biologics-based therapeutics discovery and development, and fully integrated in-house capabilities in biologic therapeutics discovery, development and manufacturing. Transcenta will have a global footprint: Discovery and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Shanghai, Beijing and Boston, US. The combined entity will have over 10 innovative pipeline molecules. Transcenta aims to shorten the timeline from target to BLA, and will make the high-quality, next-generation GMP facility available to support the development and commercialization of both in-house and strategic partner’s pipeline molecules.

“We are excited to merge with MabSpace. The newly merged entity will combine the strength of MabSpace and HJB in discovery, development and manufacturing,” said Transcenta’s executive chairman, Dr. Jonathan Y. Zhao, “MabSpace and HJB have a combined pipeline with more than 10 pre-clinical and clinical pipeline products. Leveraging the HJB’s strength in process and clinical development and integrated biomanufacturing, Transcenta will continue to create greater values by providing high-quality biologics at affordable prices to patients around the world. ”

“I would like to thank our investors from both sides for their full-hearted support of this strategic combination. With the merger of HJB and MabSpace, we can achieve a critical mass, significantly accelerate the development and commercialization of our innovative pipeline and establish Transcenta as a truly fully integrated biotherapeutics-focused global biotech company. This not only enables shorter development timeline, but also provides high-quality biotherapeutics at much lower cost to ensure affordability and sustained profitability. We hope to build Transcenta as an enduring biotech company that delivers high quality, innovative medicines to our patients and value to our shareholders around the world .” added Dr. Xueming Qian, Transcenta’s Co-Founder and CEO.

HJB and MabSpace have altogether raised approximately $160 million thus far from prominent investors, including Lilly Asia Ventures, Temasek, Sequoia Capital, ARCH Venture Partners, Teng Yue Partners and Taikang, etc. Transcenta is open to strategic collaboration with global biotech companies to further expand its portfolio and enhance its technology capabilities.

About ARCH Venture Partners

ARCH Venture Partners is one of the largest early stage technology venture firms in the U.S.  ARCH has co-founded and provided initial investments for more than 230 companies organized around life science and physical science innovations from research universities, national laboratories, corporate research groups, and entrepreneurs. 

About Lilly Asia Ventures 

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.

About Sequoia China 

The Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from our unmatched community and the lessons we’ve learned over 46 years. As “The Entrepreneurs Behind The Entrepreneurs”, Sequoia China focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology. Over the past 14 years we’ve had the privilege of working with more than 500 companies in China.

About Taikang 

Taikang is a leading insurance and financial service group in China. The company operates through three main businesses including insurance, asset management and health and elderly care. With a major investment focus in healthcare, Taikang has invested in a number of companies such as Wuxi AppTec, Mindray Medical, and Innovent Biologics.

About Temasek 

Incorporated in 1974, Temasek is a global investment company headquartered in Singapore. Supported by its network of international offices, Temasek owns a S$308 billion (US$235b, RMB1.48t) portfolio as at 31 March 2018, with significant exposure to Singapore and the rest of Asia.

About Teng Yue Partners 

Teng Yue Partners is a New York based investment firm that specializes in equity investments in China. Teng Yue utilizes a disciplined investment process based on fundamental analysis, leveraging its global perspective and local expertise.

BFC Group Ltd served as exclusive financial advisor to this transaction. Han Kun Law Offices served as counsel to this merger transaction. Sidley Austin LLP served as counsel to MabSpace.

For further information:

Media contact:

Jingyuan Qin ([e-mail])

Kathy Yuan ([e-mail])

Investor contact:

Johnathan Zhao([e-mail])

Xueming Qian ([e-mail])

Business development contact:

Kathy Yuan ([e-mail])

Chun Li ([e-mail])

近期文章

Portfolio公司新闻

行业动态

原创

欢迎关注：